🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,196 results for “GE” Clear

  1. Fibromun, Darleukin

    Philogen S.p.A.

    Patients with locally advanced Basal Cell Carcinoma (LaBCC) amenable to intratumoral injection, who have progressed or intolerant to systemic treatment.

    phase 2 small molecule active

    1 trial

  2. Fibromun, Darleukin

    Philogen S.p.A.

    Cutaneous Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  3. Fibromun, Darleukin

    Philogen S.p.A.

    Phase II, open label, multicentric, proof-of-principle basket trial in patients with malignant tumors of the skin amenable to intratumoral injection, and in a curative or neoadjuvant or palliative intention, including: • Basal cell carcinoma (BCC) • Cutaneous squamous cell carcinoma (cSCC) • Merkel cell carcinoma (MCC) • Keratoacanthoma (KA) • Malignant adnexal tumors of the skin (MATS) • Tumors from cutaneous T-cell lymphoma (CTCL) • Kaposi’s sarcoma (KS)

    phase 2 small molecule active

    1 trial

  4. Fibromun, Temozolomide SUN 100 mg hard capsules

    Philogen S.p.A.

    Glioblastoma

    phase 2 small molecule active

    1 trial

  5. Fisetin

    United Therapeutics Europe Ltd

    Femoroacetabular Impingement

    phase 2 small molecule active

    1 trial

  6. Fludarabina Accord 25 mg/ml concentrado para solución inyectable y para perfusión., HSP-CAR30, Levact 2,5 mg/ml poudre pour solution à diluer pour perfusion, RoActemra 20 mg/mL concentrate for solution for infusion, Genoxal 200 mg polvo para solución inyectable y para perfusión

    The George Institute

    Refractary or relapse non-Hodgkin T CD30+ lymphoma., Refractary or relapse Hodgkin T CD30+ lymphoma

    phase 2 small molecule active

    1 trial

  7. Fluocinolone Acetonide

    ANI PHARMACEUTICALS INC

    Age-Related Macular Degeneration

    phase 2 small molecule terminated

    1 trial

  8. Fluorouracil

    United Therapeutics Europe Ltd

    Clinical Stage II Esophageal Adenocarcinoma AJCC v8

    phase 2 small molecule active

    1 trial

  9. Fluorouracil 50mg/ml Injection., FOLINIC ACID, Eftozanermin alfa, Telisotuzumab adizutecan, Oxaliplatin 5 mg/ml concentrate for solution for infusion

    AbbVie Deutschland GmbH & Co. KG

    Adenocarcinoma of the gastroesophageal junction

    phase 2 small molecule active

    1 trial

  10. Folinezuur Kalceks 10 mg/ml oplossing voor injectie/infusie, Paclitaxel Fresenius Kabi 6 mg/ml concentraat voor oplossing voor infusie, Carboplatin Accord 10 mg/ml, concentraat voor oplossing voor infusie, Docetaxel Eugia 20 mg/ml, concentraat voor oplossing voor intraveneuze infusie, Fluorouracil Accord 50 mg/ml, oplossing voor injectie of infusie, Oxaliplatine Fresenius Kabi 5 mg/ml concentraat voor oplossing voor infusie

    Disc Medicine

    oesophageal cancer, oesophagogastric junction cancer

    phase 2 small molecule active

    1 trial

  11. Fostamatinib

    RIGEL PHARMACEUTICALS INC

    Hidradenitis Suppurativa

    phase 2 small molecule completed

    1 trial

  12. Fostamatinib

    RIGEL PHARMACEUTICALS INC

    Myelofibrosis

    phase 2 small molecule terminated

    1 trial

  13. Fostamatinib 150 mg

    RIGEL PHARMACEUTICALS INC

    IGA Nephropathy

    phase 2 small molecule completed

    1 trial

  14. Fostamatinib 150 mg bid

    RIGEL PHARMACEUTICALS INC

    Warm Antibody Autoimmune Hemolytic Anemia

    phase 2 small molecule completed

    1 trial

  15. Fostamatinib Disodium

    RIGEL PHARMACEUTICALS INC

    T Cell Lymphoma

    phase 2 small molecule completed

    1 trial

  16. Fostamatinib Disodium (R935788)

    RIGEL PHARMACEUTICALS INC

    Systemic Lupus Erythematosus

    phase 2 small molecule terminated

    1 trial

  17. Fostamatinib Disodium / R935788

    RIGEL PHARMACEUTICALS INC

    Purpura, Thrombocytopenic, Idiopathic

    phase 2 small molecule completed

    1 trial

  18. Fostamatinib Disodium tablet 100 mg

    RIGEL PHARMACEUTICALS INC

    IGA Nephropathy

    phase 2 small molecule terminated

    1 trial

  19. Fostamatinib disodium (R935788)

    RIGEL PHARMACEUTICALS INC

    Rheumatoid Arthritis

    phase 2 small molecule completed

    2 trials

  20. Furmonertinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lung Adenocarcinoma Stage III

    phase 2 small molecule active

    1 trial

  21. Furmonertinib

    Shanghai University of Traditional Chinese Medicine

    Lung Adenocarcinoma Stage III

    phase 2 small molecule active

    1 trial

  22. Futibatinib, Tecentriq 1 200 mg concentrate for solution for infusion, JNJ-61186372

    The George Institute

    Subjects with advanced solid tumour

    phase 2 small molecule active

    1 trial

  23. Fycompa 4 mg film-coated tablets, Fycompa 2 mg film-coated tablets

    Istituto Gentili S.r.l.

    White-Sutton syndrome (POGZ-Related Disorder)

    phase 2 small molecule active

    1 trial

  24. GADOTERIC ACID, [18F]fludarabine

    Pari Pharma GmbH

    Patients with newly diagnosed primary central nervous system lymphoma naïve to surgery, radiotherapy or chemotherapy

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources